Status:
COMPLETED
Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Scios, Inc.
Conditions:
Congestive Heart Failure
Renal Insufficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal...
Eligibility Criteria
Inclusion
- Decompensated heart failure hospitalization with at least 1 symptom and 1 sign of elevated filling pressures
- Admission estimated creatinine clearance =\< 50 cc/min.
Exclusion
- Systolic blood pressure \< 85 mm Hg
- Cardiogenic shock
- Volume depletion
- Myocardial infarction, unstable angina within last 30 days
- Significant valvular stenosis, hypertrophic/restrictive cardiomyopathy, or constrictive pericarditis
- Chronic hemodialysis
- Anticipated major procedure during hospitalization i.e. left heart catheterization, surgery, or transplantation
- Enrolled in another research protocol within last 30 days.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00119691
Start Date
April 1 2003
End Date
November 1 2005
Last Update
September 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115